感染症治療薬の世界市場2019-2023

【英語タイトル】Global Infectious Disease Therapeutics Market 2019-2023

Technavioが出版した調査資料(IRTNTR30461)・商品コード:IRTNTR30461
・発行会社(調査会社):Technavio
・発行日:2018年12月12日
・ページ数:120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、感染症治療薬の世界市場について調査・分析し、市場概要、市場環境、感染症治療薬市場規模、種類別(抗ウイルス剤、抗菌剤、抗真菌剤、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・感染症治療薬の世界市場概要
・感染症治療薬の世界市場環境
・感染症治療薬の世界市場動向
・感染症治療薬の世界市場規模
・感染症治療薬の世界市場:業界構造分析
・感染症治療薬の世界市場:種類別(抗ウイルス剤、抗菌剤、抗真菌剤、その他)
・感染症治療薬の世界市場:地域別市場規模・分析
・感染症治療薬の北米市場規模・予測
・感染症治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・感染症治療薬のアジア太平洋市場規模・予測
・感染症治療薬の主要国分析
・感染症治療薬の世界市場:意思決定フレームワーク
・感染症治療薬の世界市場:成長要因、課題
・感染症治療薬の世界市場:競争環境
・感染症治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、AbbVie、F. Hoffmann-La Roche、Gilead、Merck、Sanofiなどです。
【レポートの概要】

About this market
Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. Technavio’s analysts have predicted that the infectious disease therapeutics market will register a CAGR of over 4% by 2023.
Market Overview
Increasing prevalence of infectious diseases
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Availability of counterfeit drugs
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Antiviral – Market size and forecast 2018-2023
• Antibacterial – Market size and forecast 2018-2023
• Antifungal – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• F. Hoffmann-La Roche
• Gilead
• Merck
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Phase III pipeline drugs for infectious diseases
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Antiviral – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antiviral – Year-over-year growth 2019-2023 (%)
Exhibit 23: Antibacterial – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antibacterial – Year-over-year growth 2019-2023 (%)
Exhibit 25: Antifungal – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antifungal – Year-over-year growth 2019-2023 (%)
Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others – Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Pipeline drugs for infectious diseases
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie – Vendor overview
Exhibit 50: AbbVie – Business segments
Exhibit 51: AbbVie – Organizational developments
Exhibit 52: AbbVie – Geographic focus
Exhibit 53: AbbVie – Key offerings
Exhibit 54: F. Hoffmann-La Roche – Vendor overview
Exhibit 55: F. Hoffmann-La Roche – Business segments
Exhibit 56: F. Hoffmann-La Roche – Organizational developments
Exhibit 57: F. Hoffmann-La Roche – Geographic focus
Exhibit 58: F. Hoffmann-La Roche – Segment focus
Exhibit 59: F. Hoffmann-La Roche – Key offerings
Exhibit 60: Gilead – Vendor overview
Exhibit 61: Gilead – Business segments
Exhibit 62: Gilead – Organizational developments
Exhibit 63: Gilead – Geographic focus
Exhibit 64: Gilead – Segment focus
Exhibit 65: Gilead – Key offerings
Exhibit 66: Merck – Vendor overview
Exhibit 67: Merck – Business segments
Exhibit 68: Merck – Organizational developments
Exhibit 69: Merck – Geographic focus
Exhibit 70: Merck – Segment focus
Exhibit 71: Merck – Key offerings
Exhibit 72: Sanofi – Vendor overview
Exhibit 73: Sanofi – Business segments
Exhibit 74: Sanofi – Organizational developments
Exhibit 75: Sanofi – Geographic focus
Exhibit 76: Sanofi – Segment focus
Exhibit 77: Sanofi – Key offerings
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations



【掲載企業】

AbbVie、F. Hoffmann-La Roche、Gilead、Merck、Sanofi

★調査レポート[感染症治療薬の世界市場2019-2023] (コード:IRTNTR30461)販売に関する免責事項を必ずご確認ください。
★調査レポート[感染症治療薬の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆